First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis
First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background:
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system that causes the damage to the myelin sheath as well as axonal degeneration. Individuals with MS appear to have changes in the numbers and functions of T-cell subsets, leading to an immunological imbalance accompanied by enhanced autoreactivity...
Alternative Titles
Full title
First-in-human clinical trial of the NKT cell-stimulatory glycolipid OCH in multiple sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2ec57a84f74c469d8c2030fb36813dfd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2ec57a84f74c469d8c2030fb36813dfd
Other Identifiers
ISSN
1756-2864,1756-2856
E-ISSN
1756-2864
DOI
10.1177/17562864231162153
